Are you Dr. Dawson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 22 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
900 Jorie Blvd
Suite 186
Oak Brook, IL 60523Phone+1 630-954-6700
Summary
- Dr. Marcia Dawson, MD is a neonatologist in Oak Brook, Illinois. She is currently licensed to practice medicine in Illinois. She is affiliated with St. Bernard Hospital and Health Care Center.
Education & Training
Loyola University Medical CenterFellowship, Neonatal-Perinatal Medicine, 1987 - 1989
Columbus HospitalResidency, Pediatrics, 1983 - 1985
Meharry Medical CollegeClass of 1983
Certifications & Licensure
IL State Medical License 1985 - 2020
Publications & Presentations
PubMed
- 11 citationsMaximal adamantyl-substituted retinoid-related molecule-induced apoptosis requires NF-κB noncanonical and canonical pathway activation.Lulu Farhana, Marcia I. Dawson, Farhan Murshed, Joseph A. Fontana
Cell Death and Differentiation. 2011-01-01 - 550 citationsConversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3Bingzhen Lin, Siva Kumar Kolluri, Feng Lin, Wen Liu, Young-Hoon Han
Cell. 2004-02-20 - 17 citationsEvidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cellsHo-Young Lee, Marcia I. Dawson, Francois Xavier Claret, J. Don Chen, Garrett L. Walsh
Cell Growth & Differentiation. 1997-03-01
Grant Support
- LRH-1 Antagonism: Impact On Estrogen-Dependent Breast CancerNational Cancer Institute2012
- Rexinoid Synergy In Prostate Cancer ApoptosisNational Cancer Institute2005–2009
- Selective Retinoids For Breast Cancer TherapyNational Cancer Institute1999–2002
- Retinoid Design And SynthesisNational Cancer Institute1999–2002
- Selective Retinoids For Breast Cancer TherapyNational Cancer Institute1999–2000
- Michellamine B Analogs For Treatment Of HIV InfectionNational Institute Of Allergy And Infectious Diseases1998
- Selective Retinoids For Breast Cancer TherapyNational Cancer Institute1997–1998
- Retinoid Design And SynthesisNational Cancer Institute1997–1998
- Michellamine B Analogs For Treatment Of HIV InfectionNational Institute Of Allergy And Infectious Diseases1996–1998
- Receptor Selective Cancer Chemopreventive RetinoidsNational Cancer Institute1991–1995
- Targeted Therapy For HIV Infection Using AntibodiesNational Institute Of Allergy And Infectious Diseases1987–1989
- Retinoid Tumor Inhibitory Activity-Toxicity ProbeNational Cancer Institute1985–1989
- Novel Retinoids For Chemoprevention Of CancerNational Cancer Institute1986–1988
